Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group

ABSTRACT: Objective: To document antiretroviral use in Latin America during the last decade. Methods: We collected indicators from 79 HIV health care centres in 14 Latin American Spanish-speaking countries for 2013–2017. Indicators were analysed by age, sex and other characteristics and weighted by...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pedro Zitko, Martin Hojman, Sofía Sabato, Pablo Parenti, Rosana Cuini, Liliana Calanni, Jorge Contarelli, Rosa Teran, Valeria Araujo, Ioannis Bakolis, Jorge Chaverri, Miguel Morales, Ana-Belen Arauz, Wendy Moncada, Mónica Thormann, Carlos Beltrán
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/e8ea1fd4e9f949e5b26c4942d44673c5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e8ea1fd4e9f949e5b26c4942d44673c5
record_format	dspace
spelling	oai:doaj.org-article:e8ea1fd4e9f949e5b26c4942d44673c52021-11-14T04:31:14ZAntiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group1201-971210.1016/j.ijid.2021.09.047https://doaj.org/article/e8ea1fd4e9f949e5b26c4942d44673c52021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1201971221007554https://doaj.org/toc/1201-9712ABSTRACT: Objective: To document antiretroviral use in Latin America during the last decade. Methods: We collected indicators from 79 HIV health care centres in 14 Latin American Spanish-speaking countries for 2013–2017. Indicators were analysed by age, sex and other characteristics and weighted by the estimated people under care (PUC) population in each country. Results: We gathered information on 116 299 PUC. One-third belonged to centres reporting a shortage of at least one antiretroviral therapy (ART) drug for >30 days during 2017. At end 2017, 95.1% of PUC were receiving ART. During 2013–2017, 45 329 people living with HIV were admitted to 39 centres. ART initiated during the first year after admission increased from 76.7% in 2013 to 83.8% in 2017. In 35 centres across the study period, 71.7% of PUC started ART with tenofovir disoproxil fumarate and lamivudine, and zidovudine use decreased. The third most common ART drug, EFV, reached 64.8%. Raltegravir and other alternatives increased annually to almost 10% of total use in 2017. Conclusions: Initial ART in Latin America is not based on the most recent scientific evidence and recommendations; use of drugs with higher efficacy and safety profiles and guarantee of ART availability continues to be a public health challenge.Pedro ZitkoMartin HojmanSofía SabatoPablo ParentiRosana CuiniLiliana CalanniJorge ContarelliRosa TeranValeria AraujoIoannis BakolisJorge ChaverriMiguel MoralesAna-Belen ArauzWendy MoncadaMónica ThormannCarlos BeltránElsevierarticleInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 113, Iss , Pp 288-296 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Infectious and parasitic diseases RC109-216
spellingShingle	Infectious and parasitic diseases RC109-216 Pedro Zitko Martin Hojman Sofía Sabato Pablo Parenti Rosana Cuini Liliana Calanni Jorge Contarelli Rosa Teran Valeria Araujo Ioannis Bakolis Jorge Chaverri Miguel Morales Ana-Belen Arauz Wendy Moncada Mónica Thormann Carlos Beltrán Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group
description	ABSTRACT: Objective: To document antiretroviral use in Latin America during the last decade. Methods: We collected indicators from 79 HIV health care centres in 14 Latin American Spanish-speaking countries for 2013–2017. Indicators were analysed by age, sex and other characteristics and weighted by the estimated people under care (PUC) population in each country. Results: We gathered information on 116 299 PUC. One-third belonged to centres reporting a shortage of at least one antiretroviral therapy (ART) drug for >30 days during 2017. At end 2017, 95.1% of PUC were receiving ART. During 2013–2017, 45 329 people living with HIV were admitted to 39 centres. ART initiated during the first year after admission increased from 76.7% in 2013 to 83.8% in 2017. In 35 centres across the study period, 71.7% of PUC started ART with tenofovir disoproxil fumarate and lamivudine, and zidovudine use decreased. The third most common ART drug, EFV, reached 64.8%. Raltegravir and other alternatives increased annually to almost 10% of total use in 2017. Conclusions: Initial ART in Latin America is not based on the most recent scientific evidence and recommendations; use of drugs with higher efficacy and safety profiles and guarantee of ART availability continues to be a public health challenge.
format	article
author	Pedro Zitko Martin Hojman Sofía Sabato Pablo Parenti Rosana Cuini Liliana Calanni Jorge Contarelli Rosa Teran Valeria Araujo Ioannis Bakolis Jorge Chaverri Miguel Morales Ana-Belen Arauz Wendy Moncada Mónica Thormann Carlos Beltrán
author_facet	Pedro Zitko Martin Hojman Sofía Sabato Pablo Parenti Rosana Cuini Liliana Calanni Jorge Contarelli Rosa Teran Valeria Araujo Ioannis Bakolis Jorge Chaverri Miguel Morales Ana-Belen Arauz Wendy Moncada Mónica Thormann Carlos Beltrán
author_sort	Pedro Zitko
title	Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group
title_short	Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group
title_full	Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group
title_fullStr	Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group
title_full_unstemmed	Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group
title_sort	antiretroviral therapy use in selected countries in latin america during 2013–2017: results from the latin american workshop in hiv study group
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/e8ea1fd4e9f949e5b26c4942d44673c5
work_keys_str_mv	AT pedrozitko antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT martinhojman antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT sofiasabato antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT pabloparenti antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT rosanacuini antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT lilianacalanni antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT jorgecontarelli antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT rosateran antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT valeriaaraujo antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT ioannisbakolis antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT jorgechaverri antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT miguelmorales antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT anabelenarauz antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT wendymoncada antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT monicathormann antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup AT carlosbeltran antiretroviraltherapyuseinselectedcountriesinlatinamericaduring20132017resultsfromthelatinamericanworkshopinhivstudygroup
_version_	1718429990013370368

Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group

Ejemplares similares